Obezite ve Nesfatin-1 İlişkisi: Bir Meta Analiz Çalışması

Year 2021, Volume: 14 Issue: 3, 585 - 593, 15.12.2021

Burçin Altınbaş , Pinar Gunel Karadeniz

https://doi.org/10.26559/mersinsbd.982042

Abstract

Amaç: Nesfatin-1, anoreksijenik etkiye sahip tokluk peptidi olarak tanımlanan yeni bir peptittir. Çalışmalar nesfatin-1’in birçok fizyolojik faaliyetin gerçekleştirilmesinde görev aldığını göstermektedir. Öte yandan, nesfatin-1’in diyabet ve nörojenik hastalıkların yanı sıra obezite de rol oynadığı birçok çalışmada vurgulanmaktadır. Çalışmamızda, obez bireylerdeki plazma nesfatin-1 seviyelerinin obez olmayan gruplara göre anlamlı bir farka sahip olup olmadığını meta analiz ile araştırmayı amaçladık. Yöntem: Çalışmada, obez ve obez olmayan bireylerdeki plazma nesfatin-1 seviyelerini gösteren 11 çalışma (12 bulgu) değerlendirilmiştir. Tüm yaş gruplarına sahip çalışmalar ile yetişkin ve çocuk gruplarında meta analiz yapılmıştır. Rasgele etki modeli kullanılarak genel etki büyüklüğü hesaplanmıştır. p<0.05 istatistiksel olarak anlamlı kabul edilmiştir. Bulgular: Meta analiz sonuçları, tüm yaş grupları bir arada değerlendirildiğinde nesfatin-1 seviyelerinin obez gruplarda obez olmayan gruplara göre anlamlı bir azalmaya sahip olduğunu göstermektedir (p<0.05). Yetişkin ve çocuk gruplarının da meta analiz ile ayrı ayrı değerlendirilmesi sonucunda, yine obez bireylerin obez olmayan gruplara göre plazma nesfatin-1 seviyelerinin anlamlı olarak azaldığı ortaya çıkmaktadır (p<0.05). Sonuç: Sonuç olarak, meta analiz sonuçlarımız nesfatin-1’in yaştan bağımsız olarak sentez ve salınımının vücut ağırlık artışına bağlı değişim gösterebileceğine işaret etmektedir.

Keywords

Nesfatin-1, obezite, meta-analiz

The Relationship between Obesity and Nesfatin-1: A Meta-Analysis Study

Abstract

Aim: Nesfatin-1 is a new peptide defined as a satiety peptide with anorexigenic effect. Studies show that nesfatin-1 is involved in the realization of many physiological activities. On the other hand, it is emphasized in many studies that nesfatin-1 plays a role in obesity as well as diabetes and neurogenic diseases. In our study, we aimed to investigate whether plasma nesfatin-1 levels in obese individuals had a significant difference compared to non-obese groups with a meta-analysis. Method: In the study, 11 studies (12 findings) showing plasma nesfatin-1 levels in obese and non-obese individuals were evaluated. Meta-analysis were conducted in studies with all age groups and in adult and child groups. The overall effect size was calculated using the random effect model. p<0.05 was considered statistically significant. Results: Meta-analysis results showed that when all age groups were evaluated together, nesfatin-1 levels were significantly lower in obese groups than non-obese groups (p<0.05). The separate evaluation of the adult and child groups with the meta-analysis revealed that the plasma nesfatin-1 levels of obese individuals were significantly lower than the non-obese groups (p<0.05). Conclusion: In conclusion, our meta-analysis results indicated that the synthesis and release of nesfatin-1 may vary depending on body weight gain, regardless of age.

Keywords

Nesfatin-1, obesity, meta-analysis

References

• 1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–1428.
• 2. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/ plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011;96:669–73.
• 3. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105–20.
• 4. Enriori PJ, Evans AE, Sinnayah P, et al. Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab 2007;5:181–194.
• 5. Hotamisligil GS, Shargill NS, SpiegelmanBM. Adipose expression of tumour necrosis factor-α: direct role in obesity-linked insülin resistance. Science 1993;259:87–91.
• 6. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:64–73.
• 7. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709–12.
• 8. Stengel A, Tache Y. Nesfatin-1 role as possible new potent regulator of food intake. Regul Pept 2010;163:18–23.
• 9. Kohno D, Nakata M, Maejima Y, et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008;149:1295–1301.
• 10. Stengel A, Goebel M, Wang L, et al. Central nesfatin-1 reduces darkphase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor 2 receptor. Endocrinology 2009;150:4911–19.
• 11. Shimizu H, Oh-I S, Hashimoto K, et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009;150:662–71.
• 12. Pan, W, Hsuchou H, Kastin AJ. Nesfatin-1 crosses the blood–brain barrier without saturation. Peptides 2007;28(11):2223-28.
• 13. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood–brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007;28:2372-81.
• 14. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150:232–8.
• 15. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006;14(5):242-9.
• 16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548–56.
• 17. Brown RE. Could there be a fine-tuning role for brain-derived adipokines in the regulation of bodyweight and prevention of obesity? Mcgill J Med 2008;11:177–84.
• 18. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010;151: 3169-80.
• 19. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
• 20. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
• 21. Umaroglu M., Ozdemir P. metaHUN: a web tool for meta-analysis. 3rd International and 20th National Biostatistics Congress; November 26-28, 2018; Gaziantep, Turkey.
• 22. Dios O, Herrero L, Gavela-Pérez T, Soriano-Guillén L, Garcés C. Sex-specific association of plasma nesfatin-1 concentrations with obesity in children. Pediatr Obes 2019;14(12):e12567.
• 23. Anwar GM, Yamamah G, Ibrahim A, El-Lebedy D, Farid TM, Mahmoud R. Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regul Pept 2014;188:21-24.
• 24. Yin C, Liu W, Xu E, et al. Copeptin and Nesfatin-1 Are Interrelated Biomarkers with Roles in the Pathogenesis of Insulin Resistance in Chinese Children with Obesity. Ann Nutr Metab 2020;76(4):223-32.
• 25. Yosten GL, Samson WK. Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 2009;297:330-6.
• 26. Darambazar G, Nakata M, Okada T, et al. Paraventricular NUCB2/nesfatin-1 is directly targeted by leptin and mediates its anorexigenic effect. Biochem Biophys Res Commun 2015;456:913-8.
• 27. Çelik F, Belviranli M, Okudan N. Circulating levels of leptin, nesfatin-1 and kisspeptin in postmenopausal obese women. Arch Physiol Biochem 2016;122(4):195-9.
• 28. Guo Y, Xing M, Sun W, Yuan X, Dai H, Ding H. Plasma nesfatin-1 level in obese patients after acupuncture: a randomised controlled trial. Acupunct Med 2014;32(4):313-7.
• 29. Lopez-Aguilar I, Ibarra-Reynoso LDR, Malacara JM. Association of Nesfatin-1, Acylated Ghrelin and Cortisol with Scores of Compulsion, Food Addiction, and Binge Eating in Adults with Normal Weight and with Obesity. Ann Nutr Metab 2018;73(1):54-61.
• 30. Mirakhor Samani S, Ghasemi H, Bookani KR, Shokouhi B. Serum Nesfatin-1 Level in Healthy Subjects With Weight-Related Abnormalities and Newly Diagnosed Patients With Type 2 Diabetes Mellitus; A Case-Control Study. Acta Endocrinol (Buchar) 2019;5(1):69-73.
• 31. Kravchun P, Kadykova O, Narizhnaya A, Tabachenko O, Shaparenko O. Association of Circulating Adiponectin, Resistin, Irisin, Nesfatin-1, Apelin-12 and Obestatin Levels With Hypertension and Obesity. Georgian Med News 2020;(304-305):43-48.
• 32. Bloem B, Xu L, Morava E. Sex‐specific differences in the dynamics of cocaine‐ and amphetamine‐regulated transcript and nesfatin‐1 expressions in the midbrain of depressed suicide victims vs. controls. Neuropharmacology 2012;62(1):297‐303.
• 33. Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes 2013;14(3):189-95.
• 34. Kim SH, Ahn MB, Cho WK, Cho KS, Jung MH, Suh BK. The relation of serum nesfatin-1 level with anthropometric and metabolic parameters in children and adolescents: A prospective observational study. Medicine (Baltimore) 2019;98(19):e15460.
• 35. Dokumacioglu E, Iskender H, Sahin A, Erturk EY, Kaynar O. Serum levels of nesfatin-1 and irisin in obese children. Eur Cytokine Netw 2020;31(1):39-43.
• 36. Mohan H, Ramesh N, Mortazavi S, Le A, Iwakura H, Unniappan S. Unniappan. Nutrients differentially regulate nucleobindin-2/nesfatin-1 in vitro in cultured stomach ghrelinoma (MGN3-1) cells and in vivo in male mice. PLoS One 2014;9(12):e115102.
• 37. Stengel A, Hofmann T, Goebel-Stengel M, et al. Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochem. Cell Biol 2013;139(6):909-918.
• 38. Psilopanagioti A, Nikou S, Papadaki H. Nucleobindin-2/nesfatin-1 in the human hypothalamus is reduced in obese subjects and colocalizes with oxytocin, vasopressin, melanin-concentrating hormone, and cocaine- and amphetamine-regulated transcript. Neuroendocrinology 2019;108(3):190-200.